
Journal Menu
► Journal MenuJournal Browser
► Journal BrowserSpecial Issue "New Frontiers in Pathogenesis, Diagnosis, Prognosis and Treatment for Multiple Myeloma"
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 15 May 2023 | Viewed by 3165
Special Issue Editors
Interests: multiple myeloma; Waldenstrom's macroglobulinemia; lymphomas; leukemias; myeloproliferative disorders; myelodysplastic syndromes; prognosis; microenvironment; cytokines

Interests: multiple myeloma; Waldenstrom’s macroglobulinemia; amyloidosis; lymphomas; oncology
Interests: multiple myeloma; Waldenstrom’s macroglobulinemia; amyloidosis; lymphomas; oncology
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is a plasmacytic dyscrasia characterized by monoclonal paraprotein-secreting plasma cells, proliferating in the bone marrow, and accompanied by morbid manifestations such as bone pains with eventual spontaneous fractures, anemia, renal failure, possible hypercalcemia, and frequent febrile infection. The disease course is punctuated by remissions followed by relapses.
Increasing knowledge about myeloma underlining biology along with technology improvements have led to an unbelievable treatment evolution for the benefit of most patients. Likewise, with the introduction of proteasome inhibitors and IMiDs that became the basis of most therapeutic schemas, coupled with monoclonal antibodies and other new agents, the duration of responses and overall survival have been substantially prolonged, and the quality of life improved. Meanwhile, newer modalities are emerging, and some are already available, allowing the most promising ones to potentially cure for some of our patients.
Over recent years, diagnostic procedures and risk stratification strategies have adapted to the new state of management and have been improved. However, due to the emergence of aggressive myeloma sub-clones and unknown biologic processes, the disease ultimately escapes treatment control and becomes lethal. Therefore, a lot remains to be studied, evaluated, and assessed in order to reach optimal effect.
We would like to invite physicians and researchers involved in this field to contribute to this Special Issue with their observations and results.
Prof. Dr. Marie-Christine Kyrtsonis
Prof. Dr. Meletios-Athanasios Dimopoulos
Dr. Emmanouil Spanoudakis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- diagnosis procedures
- prognosis
- treatment
- biology
- prognostic factors
- pathophysiology